Choudhary Ahmed

Dr. Choudhary Ahmed

orcid
Accomplished scientist with a PhD in molecular biology and v...

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2009 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
Choudhary AhmedChoudhary Ahmed
Choudhary Ahmed
ZWZhan‐Hui Wang
Zhan‐Hui Wang
ZBZhou Bin
Zhou Bin
JCJin‐Jun Chen
Jin‐Jun Chen
MKMustafa Kamal
Mustafa Kamal
JHJin‐Lin Hou
Jin‐Lin Hou

31 January 2009 in Antiviral Research
Verified
Journal Article
Closed access
JCJinjun Chen
Jinjun Chen
ZWZhanhui Wang
Zhanhui Wang
YGYabing Guo
Yabing Guo
JPJie Peng
Jie Peng
JSJian Sun
Jian Sun
JHJinlin Hou
Jinlin Hou

14 April 2018 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
Choudhary AhmedChoudhary Ahmed
Choudhary Ahmed
PWPoppy L Winlow
Poppy L Winlow
APAimee L Parsons
Aimee L Parsons
CJCatherine L Jopling
Catherine L Jopling
Hepatitis C virus (HCV) is a positive sense RNA virus that persistently infects human liver, leading to cirrhosis and hepatocellular carcinoma. HCV replication requires the liver-specific microRNA-122 (miR-122). In contrast to canonical miRNA-mediated repression via 3′UTR sites, miR-122 positively regulates HCV replication by a direct interaction with the 5′ untranslated region (UTR) of the viral RNA. The protein factor requirements for this unusual miRNA regulation remain poorly understood. Here, we identify eIF4AII, previously implicated in miRNA-mediated repression via 3′UTR sites, as a host factor that is important for HCV replication. We demonstrate that eIF4AII interacts with HCV RNA and that this interaction is miR-122-dependent. We show that effective miR-122 binding to, and regulation of, HCV RNA are reduced following eIF4AII depletion. We find that the previously identified HCV co-factor CNOT1, which has also been implicated in miRNA-mediated repression via 3′UTR sites, contributes to regulation of HCV by eIF4AII. Finally, we show that eIF4AI knockdown alleviates the inhibition of HCV replication mediated by depletion of either eIF4AII or CNOT1. Our results suggest a competition effect between the eIF4A proteins to influence HCV replication by modulation of miR-122 function.

31 October 2023 in Virology
Verified
Journal Article
Open access
SJShahrzad Jahanshahi
Shahrzad Jahanshahi
HOHong Ouyang
Hong Ouyang
Choudhary AhmedChoudhary Ahmed
Choudhary Ahmed
AAAli Zahedi Amiri
Ali Zahedi Amiri
SDSubha Dahal
Subha Dahal
ACAlan Cochrane
Alan Cochrane
A small molecule screen identified several cardiotonic steroids (digitoxin and ouabain) and the ionophore monensin as potent inhibitors of HCoV-229E, HCoV-OC43, and SARS-CoV-2 replication with EC50s in the low nM range. Subsequent tests confirmed antiviral activity in primary cell models including human nasal epithelial cells and lung organoids. Addition of digitoxin, ouabain, or monensin strongly reduced viral gene expression as measured by both viral protein and RNA accumulation. Furthermore, the compounds acted post virus entry. While the antiviral activity of digitoxin was dependent upon activation of the MEK and JNK signaling pathways but not signaling through GPCRs, the antiviral effect of monensin was reversed upon inhibition of several signaling pathways. Together, the data demonstrates the potent anti-coronavirus properties of two classes of FDA approved drugs that function by altering the properties of the infected cell, rendering it unable to support virus replication.

7 November 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
YMYu-Qian Mao
Yu-Qian Mao
SJShahrzad Jahanshahi
Shahrzad Jahanshahi
RMRamy Malty
Ramy Malty
DODavid A. J. Van Ommen
David A. J. Van Ommen
YWYimei Wan
Yimei Wan
WHWalid A. Houry
Walid A. Houry
The COVID-19 pandemic has created a global health crisis, with challenges arising from the ongoing evolution of the SARS-CoV-2 virus, the emergence of new strains, and the long-term effects of COVID-19. Aiming to overcome the development of viral resistance, our study here focused on developing broad-spectrum pan-coronavirus antiviral therapies by targeting host protein quality control mechanisms essential for viral replication. Screening an in-house compound library led to the discovery of three candidate compounds targeting cellular proteostasis. The three compounds are (1) the nucleotide analog cordycepin, (2) a benzothiozole analog, and (3) an acyldepsipeptide analog initially developed as part of a campaign to target the mitochondrial ClpP protease. These compounds demonstrated dose-dependent efficacy against multiple coronaviruses, including SARS-CoV-2, effectively inhibiting viral replication in vitro as well as in lung organoids. Notably, the compounds also showed efficacy against SARS-CoV-2 delta and omicron strains. As part of this work, we developed a BSL2-level cell-integrated SARS-CoV-2 replicon, which could serve as a valuable tool for high-throughput screening and studying intracellular viral replication. Our study should aid in the advancement of antiviral drug development efforts.

31 December 2024 in Viruses
Verified
Journal Article
Open access
PDF file
AAALI ZAHEDI AMIRI
ALI ZAHEDI AMIRI
Choudhary AhmedChoudhary Ahmed
Choudhary Ahmed
Subha DahalSubha Dahal
Subha Dahal
FGFilomena Grosso
Filomena Grosso
HLHaomin Leng
Haomin Leng
Alan CochraneAlan Cochrane
Alan Cochrane
Treatment options for viral infections are limited and viruses have proven adept at evolving resistance to many existing therapies, highlighting a significant vulnerability in our defenses. In response to this challenge, we explored the modulation of cellular RNA metabolic processes as an alternative paradigm to antiviral development. Previously, the small molecule 5342191 was identified as a potent inhibitor of HIV-1 replication by altering viral RNA accumulation at doses that minimally affect host gene expression. In this report, we document 5342191 as a potent inhibitor of adenovirus, coronavirus, and influenza replication. In each case, 5342191-mediated reduction in virus replication was associated with altered viral RNA accumulation and loss of viral structural protein expression. Interestingly, while resistant viruses were rapidly isolated for compounds targeting either virus-encoded proteases or polymerases, we have not yet isolated 5342191-resistant variants of coronavirus or influenza. As with HIV-1, 5342191’s inhibition of coronaviruses and influenza is mediated through the activation of specific cell signaling networks, including GPCR and/or MAPK signaling pathways that ultimately affect SR kinase expression. Together, these studies highlight the therapeutic potential of compounds that target cellular processes essential for the replication of multiple viruses. Not only do these compounds hold promise as broad-spectrum antivirals, but they also offer the potential of greater resilience in combating viral infections.